Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled evaluation of the safety and efficacy of RGH-188 [cariprazine] in the acute exacerbation of schizophrenia

Next Previous
X
Search
Trial Profile

A double-blind, placebo-controlled evaluation of the safety and efficacy of RGH-188 [cariprazine] in the acute exacerbation of schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Forest Laboratories

    • Most Recent Events

    • 30 Jun 2021 Results of post -hoc analysis from NCT00404573, NCT01104779, NCT00694707, NCT01104766, NCT01104792, NCT00839852, NCT01412060, EudraCT 2012-005485-36 assessing safety Profile of Cariprazine and Potential Relevance for Patient Adherence in Schizophrenia presented at the 15th World Congress of Biological Psychiatry
    • 15 Sep 2020 Results of pooled post hoc analysis from NCT00404573, NCT01104766, NCT01104779, NCT00694707 assessing efficacy of cariprazine in the approved dose range versus placebo for reducing agitation and hostility in adult patients with an acute exacerbation of schizophrenia, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
    • 20 Sep 2016 Post hoc pooled analysis results of this (NCT00404573) and other trials (NCT01058096, NCT00694707, NCT00488618, NCT01104766, NCT01058668, NCT01104779) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top